Literature DB >> 18560909

Epidemiology of Clostridium difficile-associated disease at University Hospital Basel including molecular characterisation of the isolates 2006-2007.

L Fenner1, R Frei, M Gregory, M Dangel, A Stranden, A F Widmer.   

Abstract

A prospective study was conducted during a one-year period between 2006 and 2007 to describe the epidemiology of Clostridium difficile-associated disease (CDAD) at University Hospital Basel, Switzerland (UHBS) and to determine phenotypic and genotypic features of C. difficile strains isolated at the Microbiology Laboratory UHBS including strains from regional non-university hospitals. We prospectively identified 78 CDAD cases at UHBS with an incidence of 2.65/1,000 hospitalised patients or 2.3/10,000 patient-days. Sixteen patients (20.5%) were infected with clindamycin-resistant strains of PCR-ribotype 027 during an outbreak at the geriatric hospital. Among 124 single-patient isolates, 28 (22.6%) were resistant to moxifloxacin and 34 (27.4%) were resistant to clindamycin, but all remained susceptible to metronidazole and vancomycin. Of 102 toxigenic isolates, 19 (18.7%) had an 18-bp deletion in the tcdC gene, eight (7.8%) a 39-bp deletion, and one (1.0%) a 54-bp deletion. Genes for binary toxin were present in 27 (21.8%). PCR-ribotype 027 was associated with older age (median age 83.5 vs. 65.5 years, p < 0.0001) and longer duration of hospitalisation before onset of disease (median 15.5 vs. 9 days, p = 0.014) with a trend towards higher crude mortality, more severe disease, and previous use of macrolides compared to ribotype non-027. Overall, severe disease correlated with use of a nasogastric tube and surprisingly shorter duration of hospitalisation before onset of disease. Today, laboratory-based and epidemiological surveillance systems are required to monitor CDAD cases and emergence of new epidemic strains.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18560909     DOI: 10.1007/s10096-008-0564-9

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  23 in total

1.  Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987-2001.

Authors:  Lennox K Archibald; Shailen N Banerjee; William R Jarvis
Journal:  J Infect Dis       Date:  2004-04-20       Impact factor: 5.226

2.  First cluster of clindamycin-resistant Clostridium difficile PCR ribotype 027 in Switzerland.

Authors:  L Fenner; A F Widmer; A Stranden; M Conzelmann; A Goorhuis; C Harmanus; E J Kuijper; R Frei
Journal:  Clin Microbiol Infect       Date:  2008-05       Impact factor: 8.067

3.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

Review 4.  Emergence of Clostridium difficile-associated disease in North America and Europe.

Authors:  E J Kuijper; B Coignard; P Tüll
Journal:  Clin Microbiol Infect       Date:  2006-10       Impact factor: 8.067

5.  Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates.

Authors:  Thomas Akerlund; Bo Svenungsson; Asa Lagergren; Lars G Burman
Journal:  J Clin Microbiol       Date:  2006-02       Impact factor: 5.948

6.  Clinical features of Clostridium difficile-associated infections and molecular characterization of strains: results of a retrospective study, 2000-2004.

Authors:  Frédéric Barbut; Béatrice Gariazzo; Laetitia Bonné; Valérie Lalande; Béatrice Burghoffer; Ralucca Luiuz; Jean-Claude Petit
Journal:  Infect Control Hosp Epidemiol       Date:  2007-01-24       Impact factor: 3.254

7.  Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates.

Authors:  Patrizia Spigaglia; Paola Mastrantonio
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

8.  Characterization of toxin A-negative, toxin B-positive Clostridium difficile isolates from outbreaks in different countries by amplified fragment length polymorphism and PCR ribotyping.

Authors:  Renate J van den Berg; Eric C J Claas; Duddy H Oyib; Corné H W Klaassen; Lenie Dijkshoorn; Jon S Brazier; Ed J Kuijper
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

9.  Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates.

Authors:  F Barbut; P Mastrantonio; M Delmée; J Brazier; E Kuijper; I Poxton
Journal:  Clin Microbiol Infect       Date:  2007-09-11       Impact factor: 8.067

10.  Rapid and reliable diagnostic algorithm for detection of Clostridium difficile.

Authors:  Lukas Fenner; Andreas F Widmer; Gisela Goy; Sonja Rudin; Reno Frei
Journal:  J Clin Microbiol       Date:  2007-11-21       Impact factor: 5.948

View more
  7 in total

1.  Molecular typing and antimicrobial susceptibility testing to six antimicrobials of Clostridium difficile isolates from three Czech hospitals in Eastern Bohemia in 2011-2012.

Authors:  V Beran; E J Kuijper; C Harmanus; I M Sanders; S M van Dorp; C W Knetsch; J Janeckova; A Seidelova; L Barekova; J Tvrdik; D Chmelar; I Ciznar
Journal:  Folia Microbiol (Praha)       Date:  2017-03-22       Impact factor: 2.099

2.  Fluoroquinolone and Macrolide Exposure Predict Clostridium difficile Infection with the Highly Fluoroquinolone- and Macrolide-Resistant Epidemic C. difficile Strain BI/NAP1/027.

Authors:  Jeffrey T Wieczorkiewicz; Bert K Lopansri; Adam Cheknis; James R Osmolski; David W Hecht; Dale N Gerding; Stuart Johnson
Journal:  Antimicrob Agents Chemother       Date:  2015-11-02       Impact factor: 5.191

3.  Clostridium difficile isolates with increased sporulation: emergence of PCR ribotype 002 in Hong Kong.

Authors:  V C C Cheng; W C Yam; O T C Lam; J L Y Tsang; E Y F Tse; G K H Siu; J F W Chan; H Tse; K K W To; J W M Tai; P L Ho; K Y Yuen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-06       Impact factor: 3.267

4.  Multicenter Prevalence Study Comparing Molecular and Toxin Assays for Clostridioides difficile Surveillance, Switzerland.

Authors:  Andreas F Widmer; Reno Frei; Ed J Kuijper; Mark H Wilcox; Ruth Schindler; Violeta Spaniol; Daniel Goldenberger; Adrian Egli; Sarah Tschudin-Sutter
Journal:  Emerg Infect Dis       Date:  2020-10       Impact factor: 6.883

5.  Mortality and Clostridium difficile infection: a review.

Authors:  Brett G Mitchell; Anne Gardner
Journal:  Antimicrob Resist Infect Control       Date:  2012-05-30       Impact factor: 4.887

6.  Antimicrobial susceptibility of clostridium difficile clinical isolates in iran.

Authors:  Mehdi Goudarzi; Hossein Goudarzi; Masoud Alebouyeh; Masoumeh Azimi Rad; Farahnaz Sadat Shayegan Mehr; Mohammad Reza Zali; Mohammad Mehdi Aslani
Journal:  Iran Red Crescent Med J       Date:  2013-08-05       Impact factor: 0.611

7.  Global burden of Clostridium difficile infections: a systematic review and meta-analysis.

Authors:  Evelyn Balsells; Ting Shi; Callum Leese; Iona Lyell; John Burrows; Camilla Wiuff; Harry Campbell; Moe H Kyaw; Harish Nair
Journal:  J Glob Health       Date:  2019-06       Impact factor: 4.413

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.